Delving into the Latest Updates on Aflibercept with Synapse

Overview

Basic Info

Drug Type

Fc fusion protein

Synonyms

Aflibercept (Genetical Recombination), Aflibercept (genetical recombination) (JAN), Aflibercept (USAN/INN)

+ [13]

Target

PGF x VEGF-A

Action

inhibitors

Mechanism

PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

NeoplasmsCardiovascular DiseasesCongenital Disorders+ [7]

Active Indication

Retinopathy of PrematurityGlaucoma, NeovascularColorectal Cancer+ [17]

Inactive Indication

Advanced Colorectal AdenocarcinomaAdvanced Malignant Solid NeoplasmB-Cell Lymphoma+ [31]

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Bayer AG

Regeneron Pharmaceuticals, Inc.Bayer Korea Ltd.

+ [7]

Inactive Organization

Sanofi

Santen Pharmaceutical Co., Ltd.

License Organization

Santen Pharmaceutical Co., Ltd.

Ocular Therapeutix, Inc.

Sanofi-Aventis U.S. LLC

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (18 Nov 2011),

Wet age-related macular degeneration

RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 4715606

Source: *****

Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys, and heart, seriously affecting organ function. Nowadays, the quality of life of people has improved significantly, eating habits have changed, sugar intake is increasing, and the number of patients with DM is increasing. Statistics show that in 2017, the number of patients with DM worldwide reached 425 million (aged 20-79 years), which will exceed 600 million in 30 years; moreover, patients in low- and middle-income countries, such as China and India, account for 80 percent of the total DM population (1). According to the WHO, patients with DM worldwide increased to 366 million in 2011, which is expected to increase to 500 million in 2025, with more than 150 million patients experiencing ocular complications, such as diabetic retinopathy (DR) (2, 3). DR is a form of ocular microangiopathy and the most serious DM-related complication; it seriously endangers the health of patients with DM (4). DR pathogenesis includes increased endothelial cells in the eye capillaries, increased intimal thickness, damaged pericytes, microangioma, and damaged blood-retina barrier due to increased permeability of the blood vessels, microvascular obstruction, and neovascularization (NV) (5, 6). Currently, the prevalence of DR is 34.6% worldwide; however, it is higher in some developed countries, reaching 40.3% (7). The proportion of patients with type 1 and 2 DM suffering from blindness due to DR is 3.6% and 1.6%, respectively (8). DR is associated with significantly reduced living standards, huge medical costs, and increased social burden (9, 10).
Many anti-vascular endothelial growth factor (VEGF) drugs exist; however, the use of therapeutic drugs is strictly controlled. The main drugs recommended for treating DM-related visual complications are ranibizumab and aflibercept.

Start Date19 Oct 2025

Sponsor / Collaborator

Tanta University

NCT07205887

/ RecruitingPhase 2

A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.
All participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.

Start Date12 Sep 2025

Sponsor / Collaborator

Eyebiotech Ltd.

NCT07118670

/ Not yet recruitingPhase 4IIT

A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)

The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.

Start Date31 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Aflibercept

Login to view more data

100 Translational Medicine associated with Aflibercept

Login to view more data

100 Patents (Medical) associated with Aflibercept

Login to view more data

3,573

Literatures (Medical) associated with Aflibercept

01 Jan 2026·Ophthalmology science

Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II Trial

Article

Author: Li, Tong ; Liu, Qinghuai ; Zhang, Jie ; Han-Zhang, Han ; Lu, Shujie ; Li, Haoyu ; Jia, Huixun ; Yang, Shiqi ; Dai, Hong ; Chen, Xiaoyu ; Chen, Weiqi ; Zhu, Rongrong ; Zhou, Guohong ; Hao, Jilong ; Du, Haiwei ; Sun, Junran ; Wu, Miaoqin ; Wang, Yafang ; Song, Yanping ; Wen, Ying ; Tong, Jianping ; Wang, Wei ; Li, Chaopeng ; Zhang, Jinglin ; Wei, Wenbin ; Xiao, Xuan ; Sun, Xiaodong

Purpose:

This study aims to evaluate the efficacy and safety of high-dose efdamrofusp alfa (IBI302, targeting VEGF and complement C3b/4b) with personalized dosing intervals in patients with neovascular age-related macular degeneration (nAMD).

Design:

A multicenter, randomized, double-masked, active-controlled, noninferiority phase II trial.

Participants:

A total of 132 anti-VEGF naïve or previously treated participants with nAMD were enrolled.

Methods:

Eligible participants were randomized (1:1:1) to receive IBI302 6.4 mg, IBI302 8.0 mg, or aflibercept 2.0 mg. Efdamrofusp alfa groups were dosed every 8 weeks (Q8W) or every 12 weeks (Q12W), based on disease activity assessment at week 20, after 4 monthly injections. The aflibercept 2.0-mg group was dosed Q8W, after 3 monthly injections.

Main Outcome Measures:

The primary endpoint was the mean change in best-corrected visual acuity (BCVA) from baseline to week 40. The prespecified noninferiority margin was 4 letters.

Results:

The least squares mean (standard error) changes in BCVA from baseline to week 40 were +10.5 (1.5) letters with IBI302 6.4 mg, +9.2 (1.5) letters with IBI302 8.0 mg, and +9.7 (1.5) letters with aflibercept 2.0 mg. The estimated differences were +0.8 (80% confidence interval: -1.9 to 3.6, noninferiority test: P = 0.0115) for IBI302 6.4 mg versus aflibercept 2.0 mg and -0.5 (-3.3 to 2.2, noninferiority test: P = 0.0123) for IBI302 8.0 mg versus aflibercept 2.0 mg. Over 80% of participants in IBI302 groups were dosed Q12W after week 20 and maintained their regimens until the end of study. Treatment-emergent adverse events (TEAEs) in the study eye were reported in 36.4% of participants receiving IBI302 6.4 mg, 37.8% receiving IBI302 8.0 mg, and 23.3% receiving aflibercept 2.0 mg. The most common ocular TEAE was conjunctival hemorrhage (9.1% for 6.4 mg and 11.1% for 8.0 mg) in both IBI302 groups, whereas cataract (7.0%) was the most frequent ocular TEAE in the aflibercept 2.0-mg group.

Conclusions:

Efdamrofusp alfa 6.4 and 8.0 mg dosed up to Q12W demonstrated noninferior visual gain to aflibercept 2.0 mg Q8W. Moreover, IBI302 groups were well tolerated. These findings suggested that high-dose IBI302 with extended dosing intervals could provide sustained visual benefits for patients with nAMD.

Financial Disclosures:

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

Author: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

31 Dec 2025·DRUG DELIVERY

Safety and biocompatibility of a novel biodegradable aflibercept-drug delivery system in rhesus macaques

Article

Author: Mieler, William F. ; Shim, Jaeho ; Kang-Mieler, Jennifer J. ; Story, Brett D. ; Rudeen, Kayla M. ; Thomasy, Sara M. ; Ferneding, Michelle ; Motta, Monica ; Blandino, Andrew ; Ardon, Monica ; Roszak, Karolina ; Teixeira, Leandro B. C. ; Park, Sangwan ; Yiu, Glenn ; Le, Sophie

A clinical need exists for more effective intravitreal (IVT) drug delivery systems (DDS). This study tested the hypothesis that a novel biodegradable, injectable microsphere-hydrogel drug delivery system loaded with aflibercept (aflibercept-DDS) would exhibit long-term safety and biocompatibility in a non-human primate (NHP) model. We generated aflibercept-loaded poly (lactic-co-glycolic acid) microparticles with a modified double emulsion technique then embedded them into a biodegradable, thermo-responsive poly (ethylene glycol)-co-(L-lactic-acid) diacrylate/N-isopropylacrylamide hydrogel. Aflibercept-DDS (50 µL, 15 µg) was injected into the right eye of 23 healthy rhesus macaques. A complete ophthalmic examination, intraocular pressure (IOP), corneal pachymetry, specular microscopy, A-scan biometry, streak retinoscopy, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and electroretinography (ERG) were performed monthly. Globes from 7 NHPs were histologically examined. Aflibercept-DDS was visualized in the vitreous up to 9 months post-IVT injection, slightly impeding fundoscopy in 4 of 23 eyes; no other consistent abnormalities were appreciated during ophthalmic examination. The IOP and total retinal thickness remained normal in all animals over all timepoints. Central corneal thickness, endothelial cell density, axial globe length, and refractive error did not significantly differ from baseline. Scotopic mixed rod-cone implicit times and amplitudes along with photopic cone response implicit times and amplitudes did not significantly differ from control values. No retinal or choroidal vascular abnormalities were detected with FA and normal retinal architecture was preserved using SD-OCT. Intravitreal injection of a biodegradable aflibercept-DDS was safe and well tolerated in NHPs up to 24 months.

734

News (Medical) associated with Aflibercept

31 Oct 2025

·www.fiercepharma.com

Fierce Pharma Asia—Takeda pipeline cuts; Innovent, Lilly win against semaglutide; Roche's bispecific deal

Takeda's third-quarter pipeline cull, a head-to-head win against Novo Nordisk's semaglutide and a potential $1 billion-plus licensing deal by Roche made our news this week. Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. Roche licensed a respiratory bispecific candidate in a potential $1 billion-plus deal. And more.1. Takeda drops AstraZeneca-partnered neurological program after phase 2 failureTakeda’s AstraZeneca-partnered alpha-synuclein antibody, TAK-341/MEDI1341, has failed in a phase 2 study in multiple system atrophy. The Japanese pharma also stopped developing the orexin-2 receptor agonist danavorexton (TAK-925) for narcolepsy “due to strategic considerations,” while phase 2 development in respiratory conditions remains ongoing.2. Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyInnovent Biologics’ China-approved mazdutide has topped Novo Nordisk’s 1-mg semaglutide in a Chinese phase 3 trial conducted in patients with early-stage Type 2 diabetes and obesity. A 6-mg dose of the first-in-class GLP-1/glucagon dual receptor agonist outperformed semaglutide on the proportion of patients who met certain blood sugar and body weight benchmarks. The drug is partnered with Eli Lilly in the country.3. Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecificRoche is paying $75 million upfront and committing up to $995 million in milestones to license a long-acting TSLPxIL-33 bispecific from China’s Qyuns Therapeutics. Coded QX031N, the drug holds promise for chronic obstructive pulmonary disease and asthma, according to Qyuns. The long-acting TSLP mechanism last year attracted GSK to a $1 billion buyout of Aiolos, which got its candidate from China’s Jiangsu Hengrui Pharma.4. Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival missMerck & Co. and Eisai’s Keytruda and Lenvima failed to significantly extend patients’ lives when added to standard transarterial chemoembolization in unresectable, non-metastatic liver cancer. The overall survival miss at an interim analysis has led the pair to close the phase 3 Leap-012 trial. While an FDA expansion appears unlikely, the regimen was recently approved in China based on a positive progression-free survival readout.5. Boehringer returns to Kyowa Kirin with €640M pact for preclinical autoimmune moleculeIn a deal worth up to 640 million euros ($743 million), Boehringer Ingelheim has licensed a preclinical program from Kyowa Kirin that the German pharma hopes could become a “first-in-class … treatment of autoimmune diseases.” No details on the drug’s target or specific indications were given.6. WuXi AppTec sharpens focus by selling off China-based clinical research unitsWuXi AppTec is selling its China-based CRO WuXi Clinical and site management organization WuXi MedKey to Hillhouse. With the divestments, the company aims to emphasize its drug discovery, laboratory testing, process development and manufacturing services, according to a securities filing.7. BIO’s John Crowley urges ‘strategic action’ to strengthen FDA amid China’s biotech rise (Testimony before Congress)In a testimony before the Senate Health, Education, Labor, and Pensions Committee, Biotechnology Innovation Organization chief John Crowley called for “proactive, strategic action” to strengthen the FDA to secure “America’s biotech future” amid China’s rapid rise in biotech. His long list of recommendations includes reducing the time, cost and complexity of early drug development and improving the agency’s first-cycle review success rate.Other News of Note:8. Birds, lizards and cats, oh my: FDA blasts generic drug maker Hetero in scathing Form 4839. Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries10. Biogen boosts sales outlook on 'resilient' legacy MS franchise as new launches build momentum11. Astellas taps social media star Babs Costello to promote Izervay for geographic atrophy12. Samsung Bioepis gains full rights to Lucentis, Eylea biosimilars from Biogen in Europe (release)

Phase 3Phase 2Drug ApprovalLicense out/in

31 Oct 2025

·www.fiercebiotech.com

4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy\'s phase 3 plans

4D Molecular Therapeutics\' gene therapy is currently in a phase 3 trial for its lead indication of wet age-related macular degeneration.\n 4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in upfront cash to fund the asset’s phase 3 development.In return for the rights to develop and commercialize the gene therapy, dubbed 4D-150, for retinal vascular diseases like wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in Japan, China, Australia and other Asia-Pacific markets, Otuska is also expected to assist with cost-sharing at least $50 million over the next three years for global development activities.Further down the line, Otuska could also end up paying out up to $336 million in potential regulatory and commercial milestone payments, as well as tiered double-digit royalties should 4D-150 make it to market.4D-150 encodes aflibercept—an anti-VEGF drug Regeneron markets as Eylea—and a sequence that inhibits expression of VEGF-C. 4DMT designed 4D-150 to provide sustained delivery of anti-VEGF agents, freeing patients from burdensome injections and potentially improving outcomes.The deal comes three months after 4DMT posted 60-week data from a phase 2 trial of 4D-150 that demonstrated a 78% reduction in supplemental injections in people who received the phase 3 dose compared to projected on-label use of Eylea 2 mg.The gene therapy is currently in a phase 3 trial for wet AMD—its lead indication—with a further later-stage study for DME being lined up. The biotech said the upfront cash from the Otsuka deal would help fund this DME study as well as “pre-commercial activities.”“We are thrilled to announce this strategic partnership with Otsuka, a leading global pharmaceutical company with a strong presence in the APAC region, reflecting our shared long-term commitment to improving outcomes for patients with retinal vascular diseases,” 4DMT CEO David Kirn, M.D., said in the Oct. 30 release.“This partnership is a key pillar of our global strategy, with 4DMT continuing to lead phase 3 clinical trial and manufacturing activities globally, in addition to pre-commercial and commercial activities outside the APAC region,” Kirn added.4DMT Chief Commercial Officer Chris Simms said the Asia-Pacific region “represents a large and underserved retina market, with a high prevalence of wet AMD and DME.”“Navigating the region’s regulatory and patient-access complexities requires a strong local partner, and we expect Otsuka’s deep presence and expertise to accelerate both development of and access to 4D-150,” Simms added. It’s been a busy year for eye-related gene therapies. While Johnson & Johnson’s $130 million bet on an X-linked retinitis pigmentosa candidate suffered a phase 3 setback in May, the likes of Opus Genetics, MeiraGTx, Beacon Therapeutics and 4D Molecular Therapeutics have seen better news in the clinic.Meanwhile, the $135 million series B and Big Pharma backing secured by Stargardt disease-focused SpliceBio in June suggests investors can still be enthused, and Eli Lilly swooped in to buy Adverum last week.Otsuka has been on the lookout for opportunities to pad out its pipeline this year. The summer saw the Japanese company pay $33 million for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune and inflammatory diseases, as well as hand over $47 million for the ex-China rights to Harbour BioMed’s BCMAxCD3 bispecific candidate.

Phase 3Gene TherapyPhase 2Clinical Result

31 Oct 2025

·www.biospace.com

4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront

iStock, Enes Simsek Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection. 4D Molecular Therapeutics has signed an $85 million upfront deal with Japan’s Otsuka Pharmaceuticals to bring a genetic eye disease medicine to the Asia-Pacific region. Besides the upfront payment, 4DMT will also receive $50 million in cost sharing and will be eligible for up to $336 million in milestone payments, plus royalties, according to a Thursday press release . In return, Otsuka has secured rights to develop 4D-150 in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) in the greater Asia-Pacific (APAC) region including Japan. 4DMT will keep the rights to 4D-150 outside the APAC region. 4DMT will continue with Phase III activities for the candidate, including in the APAC region, according to the release. The biotech expects sites to open for the late-stage test in wet AMD by the end of the year. 4D-150 combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea via a single, low-dose treatment that is injected into the eye. The therapy was developed by 4DMT via its Therapeutic Vector Evolution platform to provide a longer duration treatment for patients with wet AMD and DME. Regeneron’s blockbuster Eylea is an injectable medicine that must be administered by an eye specialist every one to two months. The company is working on Eylea HD, which would be a longer-lasting pre-filled syringe of the medicine, but the new formulation has been plagued by manufacturing delays stemming from a third-party manufacturer and was rejected by the FDA earlier this week. Sales of Eylea have been declining for Regeneron; it posted $1.11 billion for the third quarter, a 28% decline. 4DMT is not the only biotech coming after Regeneron’s Eylea crown. Ocular Therapeutix has an asset called Axpaxli that William Blair has heralded as “a significant advance” for the disease, however the therapy is still years away from the market. And Kalaris Therapeutics is in Phase I with TH103 for the condition, which is one of the leading causes of blindness. Meanwhile, Eli Lilly just offered up to $261.7 million to acquire Adverum Therapeutics, which has a gene therapy candidate called Ixo-vec for wet AMD.

Phase 1AcquisitionLicense out/inPhase 3Gene Therapy

100 Deals associated with Aflibercept

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09574	Aflibercept	L01XX44 S01LA05	DB08885

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Retinopathy of Prematurity	Japan	Bayer Yakuhin Ltd.	26 Sep 2022
Glaucoma, Neovascular	Japan	Bayer Yakuhin Ltd.	25 Mar 2020
Colorectal Cancer	Japan	Sanofi KK	30 Mar 2017
Diabetic Retinopathy	United States	Regeneron Pharmaceuticals, Inc.	25 Mar 2015
Macular Edema	Japan	Bayer Yakuhin Ltd.	22 Nov 2013
Blindness	South Korea	Bayer Korea Ltd.	20 Mar 2013
Retinal Vein Occlusion	European Union	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Iceland	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Liechtenstein	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Norway	Bayer AG	21 Nov 2012
Choroidal Neovascularization	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Macular Degeneration, Age-Related, 1	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Metastatic Colorectal Carcinoma	United States	Sanofi-Aventis U.S. LLC	03 Aug 2012
Diabetic macular oedema	Australia	Bayer Australia Ltd.	07 Mar 2012
Myopic choroidal neovascularization	Australia	Bayer Australia Ltd.	07 Mar 2012
Retinal vein occlusion-related macular edema	Australia	Bayer Australia Ltd.	07 Mar 2012
Wet age-related macular degeneration	United States	Regeneron Pharmaceuticals, Inc.	18 Nov 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Edema	Phase 3	United States	Bayer AG	15 May 2023
Edema	Phase 3	China	Bayer AG	15 May 2023
Edema	Phase 3	Japan	Bayer AG	15 May 2023
Edema	Phase 3	Australia	Bayer AG	15 May 2023
Edema	Phase 3	Austria	Bayer AG	15 May 2023
Edema	Phase 3	Bulgaria	Bayer AG	15 May 2023
Edema	Phase 3	Czechia	Bayer AG	15 May 2023
Edema	Phase 3	Estonia	Bayer AG	15 May 2023
Edema	Phase 3	France	Bayer AG	15 May 2023
Edema	Phase 3	Georgia	Bayer AG	15 May 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03712904 (CTgov)	Phase 2	Uveal Melanoma	3	Stereotactic Body Radiation Therapy (A. Stereotactic Body Radiation Therapy, Ziv-aflibercept)	yxmmdpisjq = nvdhhwjqgw fvxjkaggdb (xlegaxouye, buwhkrqjxb - rvkfxascwt) View more	-	24 Sep 2025
				Ziv-Aflibercept (B. Stereotactic Body Radiation Therapy, Ziv-aflibercept)	yxmmdpisjq = wpuceeyowx fvxjkaggdb (xlegaxouye, skwwmkledi - lxqpwalkrq) View more
EURETINA2025	Not Applicable	Wet age-related macular degeneration	181	Intravitreal anti-VEGF (ranibizumab or aflibercept)	qhnlyybklr(ijeucpxqao) = iggniblblq vfmeuukjbv (xoimfmmpfj )	Positive	04 Sep 2025
NCT05850520 (QUASAR, EURETINA2025)	Phase 3	Retinal vein occlusion-related macular edema	869	aflibercept 8q8/3	ktgollkevd(hnunwxfejw) = ezkvltjbak bxqsaythxz (lontduatbf, 1.1) View more	Positive	04 Sep 2025
				aflibercept 8q8/5	ktgollkevd(hnunwxfejw) = qeztvntalw bxqsaythxz (lontduatbf, 1.0) View more
PULSAR Extension (EURETINA2025)	Phase 3	Wet age-related macular degeneration	208	aflibercept 2mg→8mg	dmqixewils(wcdoqmfijp) = jgbajzgafj gpwkiqblmh (hwbomjcark ) View more	Positive	04 Sep 2025
ATRIA (EURETINA2025)	Not Applicable	Retinal vein occlusion-related macular edema \| Diabetic macular oedema \| Wet age-related macular degeneration	148	Tyalia 2mg	sandypzqbq(yswmgbmcqc) = yefalzumxr ofavxyelku (spesulowtd ) View more	Positive	04 Sep 2025
NCT04423718 (PULSAR, EURETINA2025)	Phase 3	Wet age-related macular degeneration	625	aflibercept 8mg	uwlnqpcfiq(seffadjskx) = yycgpgnunx bmuaruxapf (jhwscjzqqj ) View more	Positive	04 Sep 2025
				aflibercept 2mg→8mg	uwlnqpcfiq(seffadjskx) = pqwrshiupr bmuaruxapf (jhwscjzqqj ) View more
NCT04423718 (PULSAR, EURETINA2025)	Phase 3	Polypoidal choroidal vasculopathy	625	aflibercept 2mg→8mg (Type 1)	dhfgryekib(xencghwiqe) = urptwwljwy ngfwtixbxk (zlosvdzeqe ) View more	Positive	04 Sep 2025
				aflibercept 8mg (Type 1)	dhfgryekib(xencghwiqe) = rhxbswlqog ngfwtixbxk (zlosvdzeqe ) View more
PULSAR (EURETINA2025)	Phase 3	Wet age-related macular degeneration	1,009	aflibercept 2 mg every 8 weeks (2q8)	hlsfxbipxj(etcrxlaoch) = rzebvugzkx qhxnodedfb (hjldiameeo ) View more	Positive	04 Sep 2025
				aflibercept 8 mg every 12 weeks (8q12)	hlsfxbipxj(etcrxlaoch) = fuiynhdccz qhxnodedfb (hjldiameeo ) View more
EURETINA2025	Not Applicable	Wet age-related macular degeneration	182	Aflibercept 8 mg	bugxfgyasd(gddzggcbrp) = Safety was favorable, with only one mild inflammatory event and no intraocular pressure (IOP) issues observed. papvzyldvb (esvncfyefs )	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Wet age-related macular degeneration	204	Aflibercept 8mg (switched from another VEGF inhibitor)	neodprnand(guevwpmnck) = whmtkuvtup rmpculkfbv (ognblrewfh ) View more	Positive	04 Sep 2025
				Aflibercept 8mg (treatment-naive)	qjujtujohf(ijstbuvuea) = wesslwjglm ekevpstlwl (myqveqjvxe ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.